Skip to main content
Erschienen in: Clinical Rheumatology 2/2009

01.02.2009 | Brief Report

Complementary and alternative medicines in ankylosing spondylitis: a cross-sectional study

verfasst von: Simon M. Chatfield, Shyamali C. Dharmage, Anthony Boers, Belinda J. Martin, Russell R. C. Buchanan, Walter P. Maksymowych, Lionel Schachna

Erschienen in: Clinical Rheumatology | Ausgabe 2/2009

Einloggen, um Zugang zu erhalten

Abstract

Prevalence of dietary complementary and alternative medicine (CAM) and consultation with a CAM practitioner was examined in a cross-sectional study of 75 AS patients. Seventy one of 75 (94.7%) study participants reported previous or current CAM use. Among these AS patients, 44 (72.1%) reported dietary CAM use and 27 (36.0%) were seeing a CAM practitioner at the time of study. Of 89 dietary CAM, 50 (56.4%) were perceived to be of slight or no benefit, and only 10 (11.2%) were initiated by a CAM practitioner. Compared with non-users, current dietary CAM users were more likely to be female (OR 6.5; 95% CI, 1.8–23.9). Patients attending a CAM practitioner were more likely to have university education (OR 5.7; 95% CI, 1.5–21.9) and higher BASDAI (OR 1.3; 95%CI, 1.0–1.7). Despite low rates of perceived benefit, dietary CAM use and CAM practitioner attendance is common among AS patients.
Literatur
2.
Zurück zum Zitat van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J et al (2006) Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54:2136–2146PubMedCrossRef van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J et al (2006) Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54:2136–2146PubMedCrossRef
3.
Zurück zum Zitat Jois RN, Gaffney K, Keat A (2007) Anti-tumour necrosis factor therapy for ankylosing spondylitis-unresolved issues. Rheumatology 46:899–901PubMedCrossRef Jois RN, Gaffney K, Keat A (2007) Anti-tumour necrosis factor therapy for ankylosing spondylitis-unresolved issues. Rheumatology 46:899–901PubMedCrossRef
4.
Zurück zum Zitat Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275–2285PubMedCrossRef Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275–2285PubMedCrossRef
5.
Zurück zum Zitat Rao JK, Mihaliak K, Kroenke K, Bradley J, Tierney WM, Weinberger M (1999) Use of complementary therapies for arthritis among patients of rheumatologists. Ann Intern Med 131:409–416PubMed Rao JK, Mihaliak K, Kroenke K, Bradley J, Tierney WM, Weinberger M (1999) Use of complementary therapies for arthritis among patients of rheumatologists. Ann Intern Med 131:409–416PubMed
6.
Zurück zum Zitat Cronan TA, Kaplan RM, Posner L, Blumberg E, Kozin F (1989) Prevalence of the use of unconventional remedies for arthritis in a metropolitan community. Arthritis Rheum 32:1604–1607PubMedCrossRef Cronan TA, Kaplan RM, Posner L, Blumberg E, Kozin F (1989) Prevalence of the use of unconventional remedies for arthritis in a metropolitan community. Arthritis Rheum 32:1604–1607PubMedCrossRef
7.
Zurück zum Zitat Buchbinder R, Gingold M, Hall S, Cohen M (2002) Non-prescription complementary treatments used by rheumatoid arthritis patients attending a community-based rheumatology practice. Intern Med J 32:208–214PubMedCrossRef Buchbinder R, Gingold M, Hall S, Cohen M (2002) Non-prescription complementary treatments used by rheumatoid arthritis patients attending a community-based rheumatology practice. Intern Med J 32:208–214PubMedCrossRef
8.
Zurück zum Zitat Zochling J, March L, Lapsley H, Cross M, Tribe K, Brooks P (2004) Use of complementary medicines for osteoarthritis—a prospective study. Ann Rheum Dis 63:549–554PubMedCrossRef Zochling J, March L, Lapsley H, Cross M, Tribe K, Brooks P (2004) Use of complementary medicines for osteoarthritis—a prospective study. Ann Rheum Dis 63:549–554PubMedCrossRef
9.
Zurück zum Zitat Herman CJ, Allen P, Hunt WC, Prasad A, Brady TJ (2004) Use of complementary therapies among primary care clinic patients with arthritis. Prev Chronic Dis 1:A12PubMed Herman CJ, Allen P, Hunt WC, Prasad A, Brady TJ (2004) Use of complementary therapies among primary care clinic patients with arthritis. Prev Chronic Dis 1:A12PubMed
10.
Zurück zum Zitat Cronan TA, Kaplan RM, Kozin F (1993) Factors affecting unprescribed remedy use among people with self-reported arthritis. Arthritis Care Res 6:149–155PubMedCrossRef Cronan TA, Kaplan RM, Kozin F (1993) Factors affecting unprescribed remedy use among people with self-reported arthritis. Arthritis Care Res 6:149–155PubMedCrossRef
11.
Zurück zum Zitat Moore AD, Petri MA, Manzi S, Isenberg DA, Gordon C, Senecal JL et al (2000) The use of alternative medical therapies in patients with systemic lupus erythematosus. Trination Study Group. Arthritis Rheum 43:1410–1418PubMedCrossRef Moore AD, Petri MA, Manzi S, Isenberg DA, Gordon C, Senecal JL et al (2000) The use of alternative medical therapies in patients with systemic lupus erythematosus. Trination Study Group. Arthritis Rheum 43:1410–1418PubMedCrossRef
12.
Zurück zum Zitat Fautrel B, Adam V, St-Pierre Y, Joseph L, Clarke AE, Penrod JR (2002) Use of complementary and alternative therapies by patients self-reporting arthritis or rheumatism: results from a nationwide canadian survey. J Rheumatol 29:2435–2441PubMed Fautrel B, Adam V, St-Pierre Y, Joseph L, Clarke AE, Penrod JR (2002) Use of complementary and alternative therapies by patients self-reporting arthritis or rheumatism: results from a nationwide canadian survey. J Rheumatol 29:2435–2441PubMed
13.
Zurück zum Zitat Haugen M, Kjeldsen-Kragh J, Nordvag BY, Forre O (1991) Diet and disease symptoms in rheumatic diseases—results of a questionnaire based survey. Clin Rheumatol 10:401–407PubMedCrossRef Haugen M, Kjeldsen-Kragh J, Nordvag BY, Forre O (1991) Diet and disease symptoms in rheumatic diseases—results of a questionnaire based survey. Clin Rheumatol 10:401–407PubMedCrossRef
14.
Zurück zum Zitat Ramos-Remus C, Watters CA, Dyke L, Suarez-Almazor ME, Russell AS (1999) Assessment of health locus of control in the use of nonconventional remedies by patients with rheumatic diseases. J Rheumatol 26:2468–2474PubMed Ramos-Remus C, Watters CA, Dyke L, Suarez-Almazor ME, Russell AS (1999) Assessment of health locus of control in the use of nonconventional remedies by patients with rheumatic diseases. J Rheumatol 26:2468–2474PubMed
15.
Zurück zum Zitat van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361–368PubMedCrossRef van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361–368PubMedCrossRef
16.
Zurück zum Zitat Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286–2291PubMed Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286–2291PubMed
17.
Zurück zum Zitat Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Mallorie P et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281–2285PubMed Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Mallorie P et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281–2285PubMed
18.
Zurück zum Zitat Doward LC, Spoorenberg A, Cook SA, Whalley D, Helliwell PS, Kay LJ et al (2003) Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 62:20–26PubMedCrossRef Doward LC, Spoorenberg A, Cook SA, Whalley D, Helliwell PS, Kay LJ et al (2003) Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 62:20–26PubMedCrossRef
19.
Zurück zum Zitat Jones SD, Steiner A, Garrett SL, Calin A (1996) The Bath Ankylosing Spondylitis Patient Global Score (BAS-G). Br J Rheumatol 35:66–71PubMedCrossRef Jones SD, Steiner A, Garrett SL, Calin A (1996) The Bath Ankylosing Spondylitis Patient Global Score (BAS-G). Br J Rheumatol 35:66–71PubMedCrossRef
20.
Zurück zum Zitat Australian bureau of statistics, Commonwealth of Australia. Socioeconomic indexes for areas (SEIFA) Volume 1.1. Australian bureau of statistics: Canberra, Australia, 2001 Australian bureau of statistics, Commonwealth of Australia. Socioeconomic indexes for areas (SEIFA) Volume 1.1. Australian bureau of statistics: Canberra, Australia, 2001
21.
Zurück zum Zitat Feldman DE, Duffy C, De Civita M, Malleson P, Philibert L, Gibbon M et al (2004) Factors associated with the use of complementary and alternative medicines in juvenile idiopathic arthritis. Arthritis Rheum 51:527–532PubMedCrossRef Feldman DE, Duffy C, De Civita M, Malleson P, Philibert L, Gibbon M et al (2004) Factors associated with the use of complementary and alternative medicines in juvenile idiopathic arthritis. Arthritis Rheum 51:527–532PubMedCrossRef
22.
Zurück zum Zitat MacLennan AH, Wilson DH, Taylor AW (1996) Prevalence and cost of alternative medicine in Australia. Lancet 347:569–573PubMedCrossRef MacLennan AH, Wilson DH, Taylor AW (1996) Prevalence and cost of alternative medicine in Australia. Lancet 347:569–573PubMedCrossRef
23.
Zurück zum Zitat Sundstrom B, Stalnacke K, Hagfors L, Johansson G (2006) Supplementation of omega-3 fatty acids in patients with ankylosing spondylitis. Scand J Rheumatol 35:359–362PubMedCrossRef Sundstrom B, Stalnacke K, Hagfors L, Johansson G (2006) Supplementation of omega-3 fatty acids in patients with ankylosing spondylitis. Scand J Rheumatol 35:359–362PubMedCrossRef
24.
Zurück zum Zitat Vecchio PC (1994) Attitudes to alternative medicine by rheumatology outpatient attenders. J Rheumatol 21:145–147PubMed Vecchio PC (1994) Attitudes to alternative medicine by rheumatology outpatient attenders. J Rheumatol 21:145–147PubMed
Metadaten
Titel
Complementary and alternative medicines in ankylosing spondylitis: a cross-sectional study
verfasst von
Simon M. Chatfield
Shyamali C. Dharmage
Anthony Boers
Belinda J. Martin
Russell R. C. Buchanan
Walter P. Maksymowych
Lionel Schachna
Publikationsdatum
01.02.2009
Verlag
Springer-Verlag
Erschienen in
Clinical Rheumatology / Ausgabe 2/2009
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-008-1029-3

Weitere Artikel der Ausgabe 2/2009

Clinical Rheumatology 2/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

03.06.2024 NSCLC Nachrichten

Wie stark Menschen mit fortgeschrittenem NSCLC von einer Therapie mit Immun-Checkpoint-Hemmern profitieren, hängt offenbar auch davon ab, wie sehr die Diagnose ihre psychische Verfassung erschüttert

Antikörper mobilisiert Neutrophile gegen Krebs

03.06.2024 Onkologische Immuntherapie Nachrichten

Ein bispezifischer Antikörper formiert gezielt eine Armee neutrophiler Granulozyten gegen Krebszellen. An den Antikörper gekoppeltes TNF-alpha soll die Zellen zudem tief in solide Tumoren hineinführen.

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.